Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: A report from the children's cancer group

Blood

Volumn 87, Issue 12, 1996, Pages 4979-4989

  Woods, William G ^a   Kobrinsky, Nathan ^b   Buckley, Jonathan D ^b   Lee, Jae Won ^b   Sanders, Jean ^b   Neudorf, Steven ^b   Gold, Stuart ^b   Barnard, Dorothy R ^b   DeSwarte, Joetta ^b   Dusenbery, Kathryn ^b   Kalousek, Dagmar ^b   Arthur, Diane C ^b   Lange, Beverly J ^b  

^a CHILDREN S ONCOLOGY GROUP   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; ASPARAGINASE; AZACITIDINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; METHOTREXATE; TIOGUANINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW BIOPSY; BONE MARROW PURGING; BONE MARROW RESCUE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CHILD; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEVER; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN TISSUE; INFANT; INTRAMUSCULAR DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 8944249286     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.12.4979.bloodjournal87124979     Document Type: Article

References (45)

1. Buckley JD, Chard RL, Baehner RL, Nesbit ME, Lampkin BC, Woods WG, Hammond GD: Improvement in outcome for children with acute non-lymphocytic leukemia: A report from the Childrens Cancer Study Group. Cancer 63:1457, 1989
2. Stone RM, Mayer RJ: Treatment of the newly diagnosed adult with de novo acute myeloid leukemia. Hemat Oncol Clin North Am 7:47, 1993
3. Wells RJ, Woods WG, Buckley JD, Odom LF, Benjamin D, Bernstein I, Betcher D, Feig S, Kim T, Ruymann F, Smithson W, Srivastava A, Tannous R, Buckley CM, Whitt JK, Wolff L, Lampkin BC: Treatment of newly diagnosed children and adolescents with acute myeloid leukemia - A Childrens Cancer Group study. J Clin Oncol 12:2367, 1994
4. Yates J, Glidewell O, Wieraik P, Cooper MR, Steinberg D, Dosik H, Levy R, Hoagland C, Henry P, Gottlieb A, Cornell C, Berenberg J, Hutchin JL, Raich P, Nissen N, Ellison RR, Frelick R, James GW, Falkson G, Silver RT, Haurani F, Green M, Henderson E, Leone L, Holland JF: Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: A CALGB study. Blood 60:454, 1982
5. Wolff SN, Herzig RH, Fay JW, Phillips GL, Lazarus HM, Flexner JM, Stein RS, Greer JP, Cooper B, Herzig GP: High dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: Long-term follow up and results. J Clin Oncol 7:1260, 1989
6. Buckley J, Lampkin B, Nesbit M, Bernstein ID, Feig SA, Kersey JH, Piomelli S, Kim T, Hammond GD: Remission induction of first remission in children with acute non-lymphocytic leukemia using cytosine arabinoside and doxorubicin or daunorubicin. Med Pediatr Oncol 17:382, 1989
7. Cassileth PA, Lynch E, Hines J, Oken MM, Mazza JJ, Bennett JM, McGlave PB, Edelstein M, Harrington DP, O'Connell MJ: Varying intensity of postremission therapy in acute myeloid leukemia. Blood 79:1924, 1992
8. Mayer RJ, Davies RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E III, for the Cancer and Leukemia Group B: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896, 1994
9. Clift RA, Buckner CD, Thomas ED, Kopecky KJ, Appelbaum FR, Tallman M, Storb R, Sanders J, Sullivan K, Banaji M, Beatty PS, Bensinger W, Cheever M, Deeg J, Doney K, Fefer A, Greenberg P, Hansen JA, Hackman R, Hill R, Martin P, Meyers J, McGuffin R, Neiman P, Sale G, Shulman H, Singer J, Stewart P, Weiden P, Witherspoon R: The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant 2:243, 1987
10. McGlave P, Haake R, Bostrom B, Brunning R, Hurd DD, Kim TH, Nesbit ME, Vercellotti GM, Weisdorf D, Woods WG, Ramsay NKC, Kersey JH: Allogeneic bone marrow transplantation for acute non-lymphocytic leukemia in first remission. Blood 72:1512, 1988
11. Stuart RK: Autologous bone marrow transplantation for leukemia. Semin Oncol 20:40, 1993
12. Lampkin B, Nagao T, Mauer A: Synchronization and recruitment in acute leukemia. J Clin Invest 50:2204, 1971
13. Lampkin B, McWilliams N, Mauer A, Flessa H, Hake D, Fisher V: Manipulation of the mitotic cycle in the treatment of acute myelogenous leukemia. Br J Haematol 32:29, 1976
14. Karp JE, Burke PJ: Enhancement of drug cytotoxicity by recruitment of leukemic myeloblasts with humoral stimulation. Cancer Res 36:3600, 1976
15. Karp JE, Donehower RC, Enterline JP, Dole GB, Fox MG, Burke PJ: In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia. Blood 73:24, 1989
16. Burke PJ, Karp JE, Braine HG, Vaughan WP: Timed sequential therapy of human leukemia based upon the response of leukemic cells to humoral growth factors. Cancer Res 37:2138, 1977
17. Vaughan WP, Karp JE, Burke PJ: Long chemotherapy-free remissions after single-cycle timed-sequential chemotherapy for acute myelocytic leukemia. Cancer 45:859, 1980
18. Vaughan WP, Karp JE, Burke PJ: Two-cycle timed-sequential chemotherapy for adult acute nonlymphocytic leukemia. Blood 64:975, 1984
19. Capizzi RL, Poole M, Cooper MR, Richards F II, Stuart JJ, Jackson DV Jr, White DR, Spurr Cl, Hopkins JO, Muss HB, Rudnick SA, Wells R, Gabriel D, Ross D: Treatment of poor risk acute leukemia with sequential high-dose Ara-C and asparaginase. Blood 63:694, 1984
20. Woods WG, Ruymann FB, Lampkin BC, Buckley JD, Bernstein ID, Srivastava AK, Smithson WA, Benjamin DR, Feig SA, Kim TH, Odom LF, Wells RJ, Hammond GD: The role of timing of high dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia. Cancer 66:1106, 1990
21. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C: Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British Cooperative Group. Ann Intern Med 103:620, 1985
22. Seargeant LE, Kobrinsky NL, Sus CJ, Nazeravich DR: In vitro stability and compatibility of daunorubicin, cytarabine, and etoposide. Cancer Treat Rep 71:1189, 1987
23. Yeager AM, Kaizer H, Santos GW, Saral R, Colvin OM, Stuart RK, Braine HG, Burke PJ, Ambinder RF, Burns WH, Fuller DJ, Davis JM, Karp JE, May S, Rowley SC, Sensenbrenner LL, Vogelsang GB, Wingard JR: Autologous bone marrow transplantation in patients with acute non-lymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med 315:141, 1986
24. Woods WG, Kobrinsky N, Buckley J, Neudorf S, Sanders J, Miller L, Barnard D, Benjamin D, DeSwarte J, Kolousek D, Shina D, Hammond GD, Lange BJ: Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: A Childrens Cancer Group pilot study. J Clin Oncol 11:1448, 1993
25. Nesbit ME, Buckley JD, Feig SA, Anderson JR, Lampkin B, Bernstein ID, Kim TH, Piomelli S, Kersey JH, Coccia PF, O'Reilly RC, August C, Thomas ED, Hammond GD: Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by marrow transplantation for multiagent chemotherapy: A report from the Childrens Cancer Group. J Clin Oncol 12:127, 1994
26. Baehner RL, Bernstein ID, Sather H, Higgins G, McCreadie S, Chard RL, Hammond D: Contrasting benefits of two maintenance programs following identical induction in children with acute nonlymphocytic leukemia: A report from the Childrens Cancer Study Group. Cancer Treat Rep 68:1269, 1984
27. Peto R, Peto J: Asymptotically efficient rank in variant test procedures. J R Stat Soc (A) 135:185, 1972
28. Greenwood M: The natural duration of cancer. Reports on Public Health and Medical Subjects, 33. London, UK, Her Majesty's Stationery Office, 1926, p 1
29. Skipper HE, Schabel FM, Jay R, Wilcox WS: Experimental evaluation of potential antitumor agents: On the criteria and kinetics associated with curability of experimental leukemia. Cancer Chemother Rep 35:1, 1964
30. Frei E, Canellos GP: Dose: A critical factor in cancer chemotherapy. Am J Med 69:585, 1980
31. Patte C, Philip T, Rodary C, Zucker J-M, Behrendt H, Gentet J-C, Lamagnere J-P, Otten J, Dufillot D, Pein F, Caillou B, Lemerle J: High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: Results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol 9:123, 1991
32. Finlay JL, Anderson JR, Cecalupo AJ, Hutchinson RJ, Kadin ME, Kjeldsberg CR, Provisor AJ, Woods WG, Meadows AT: Disseminated nonlymphoblastic lymphoma of childhood: A Childrens Cancer Group Study, CCG-552. Med Pediatr Oncol 23:453, 1994
33. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, Moore A, Ellerton JA, Norton L, Ferrer CR, Colangelo Ballow A, Frei E III, Henderson IC: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253, 1994
34. Mayer RJ: Current chemotherapeutic treatment approaches to the management of previously untreated adults with de novo acute myelogenous leukemia. Semin Oncol 14:384, 1987
35. Bishop JF, Young GA, Szer J, Matthews JP, Page A: Randomized trial of high dose cylosine arabinoside (ara-C) combination in induction in acute myeloid leukemia (AML). Proc Am Soc Clin Oncol 11:260, 1992 (abstr)
36. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, Bradstock K, Enno A, Wolf M, Fox R, Cobcroft R, Herrmann R, Van Der Weyden M, Juneja S: High dose cytosine arabinoside (ara-C) in induction prolongs remission in acute myeloid leukemia (AML). Updated results of a randomized phase III trial. Blood 84:232a, 1994 (abstr, suppl 1)
37. Woods WG: Childrens Cancer Group Protocol CCG-2891: A phase III randomized trial of intensive schedule versus standard schedule induction chemotherapy with DNM/AraC/VP16/6-TG/DM and of autologous BMT versus combination chemotherapy for intensification in children with ANLL or myelodysplastic syndrome. Bethesda, MD, US National Cancer Institute, PDQ Protocol Document 9785, 1994
38. Simone JV: Factors that influence haematological remission duration in acute lymphocytic leukaemia. Br J Haematol 32:465, 1976
39. Frei E III, Sallan SE: Acute lymphoblastic leukemia: Treatment. Cancer 42:828, 1978
40. Archimbaud E, Thomas X, Leblond V, Michallet M, Fenoux P, Cordonnier C, Dreyfus F, Troussard X, Jaubert J, Travade P, Troncy J, Assouline D, Fiere D: Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: Long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. J Clin Oncol 13:11, 1995
41. Geller RB, Saral R, Piantadosi S, Zahurak M, Vogelsang GB, Wingard ZJR, Ambinder RF, Beschorner WB, Braine HG, Burns WH, Hess AD, Jones RJ, May WS, Rowley SC, Wagner JE, Yeager AM, Santos GW: Allogeneic bone marrow transplantation after high dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia. Blood 73:2209, 1989
42. Snyder DS, Chao NJ, Amylon MD, Taguchi J, Long GD, Negrin RS, Nademanee AP, O'Donnell MR, Schmidt GM, Stein AS, Parker PM, Smith EP, Stephen DE, Molina A, Lipsett JA, Hoppe RT, Niland JC, Dagis AC, Wong RM, Forman SJ, Blume KG: Fractionated total body irradiation and high dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission. Blood 82:2920, 1993
43. Dinsmore R, Kirkpatrick D, Flomenberg N, Gulati S, Kapoor N, Brochstein J, Shank B, Reid A, Groshen S, O'Reilly RJ: Allogeneic bone marrow transplantation for patients with acute nonlymphocytic leukemia. Blood 63:649, 1984
44. Ringden O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindelev L, Parkkali T, Lenhoff S, Seilerfore B, Ljungman P, Mallander L, Jacobson N for the Nordic Bone Marrow Transplantation Group: A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: A report from the Nordic Bone Marrow Transplantation Group. Blood 83:2723, 1994
45. Archimbaud E, Thomas X, Michallet M, Jaubert J, Troncy J, Guyatat D, Fiare D: Prospective genetically randomized comparison between intensive post induction chemotherapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukemia. J Clin Oncol 12:262, 1994